UCB to Acquire Antibody‑Therapy Maker for Autoimmune Diseases Amid Visa and Funding Challenges
Stat News reports that biotech firm UCB plans to acquire a developer of antibody treatments for autoimmune diseases, expanding its therapeutic pipeline. The article also notes broader industry pressures, including U.S. visa delays that are driving international scientists away, new funding for gene‑therapy startup Latus Bio, and tightening regulatory conditions in China. A separate STAT+ newsletter (ID 28252) also mentions "another UCB deal" but provides only a brief reference without the visa, funding, or China context, confirming the acquisition while lacking the additional details.